EGFR and non-small cell lung carcinoma: Also, the popular tyrosine kinase inhibitor (TKI) application has been well testified to benefit NSCLC patients with epidermal growth factor receptor (EGFR) mutations (Ke and Wu, 2016; Zhou et al., 2020).